PURPOSE: In this study we evaluated the activity and toxicity of a combination of 5-fluorouracil continuous infusion and vinorelbine as second or third line chemotherapy in metastatic breast cancer (MBC). PATIENTS AN METHODS: A total 24 patients who had received doxorrubicin and/or paclitaxel were included in this study. The regimen consisted in 5-fluorouracil 1 gr/m(2) BSA continuous infusion for 3 days and vinorelbine 30 mg/m(2) intravenous (IV) on day 1. The cycles were repeated every 21 days for 6 cycles. RESULTS: Objective responses were recorded in 37.5% (12.5% complete remission). The median disease-free survival was calculated 6.33 +/- 8.12 months (CI 95% of 3.43 months). Toxicity was observed in 12.5% of the patients and no treatment related deaths were recorded. CONCLUSION: The combination of 5-fluorouracil/vinorelbine at the dose administered is an effective regime in patients with MBC, with low toxicity and cost.
PURPOSE: In this study we evaluated the activity and toxicity of a combination of 5-fluorouracil continuous infusion and vinorelbine as second or third line chemotherapy in metastatic breast cancer (MBC). PATIENTS AN METHODS: A total 24 patients who had received doxorrubicin and/or paclitaxel were included in this study. The regimen consisted in 5-fluorouracil 1 gr/m(2) BSA continuous infusion for 3 days and vinorelbine 30 mg/m(2) intravenous (IV) on day 1. The cycles were repeated every 21 days for 6 cycles. RESULTS: Objective responses were recorded in 37.5% (12.5% complete remission). The median disease-free survival was calculated 6.33 +/- 8.12 months (CI 95% of 3.43 months). Toxicity was observed in 12.5% of the patients and no treatment related deaths were recorded. CONCLUSION: The combination of 5-fluorouracil/vinorelbine at the dose administered is an effective regime in patients with MBC, with low toxicity and cost.
Authors: L Romero Acuña; M Langhi; J Pérez; J Romero Acuña; M Machiavelli; J Lacava; C Vallejo; A Romero; H Fasce; E Ortiz; S Grasso; S Amato; R Rodríguez; M Barbieri; B Leone Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: E Esteban; G de Sande; J Puertas; J Fra; I Palacio; J M Vieitez; J L Fernández; I Muñiz; A Modollel; J Carrasco; M Sala; A J Lacave Journal: Breast Cancer Res Treat Date: 2000-07 Impact factor: 4.872
Authors: R Hansen; E Quebbeman; P Beatty; P Ritch; T Anderson; D Jenkins; J Frick; R Ausman Journal: Breast Cancer Res Treat Date: 1987-11 Impact factor: 4.872
Authors: A Romero; M G Rabinovich; C T Vallejo; J E Perez; R Rodriguez; M A Cuevas; M Machiavelli; J A Lacava; M Langhi; L Romero Acuña Journal: J Clin Oncol Date: 1994-02 Impact factor: 44.544
Authors: G Freyer; T Delozier; M Lichinister; D Gedouin; P Bougnoux; P His; K Imadalou; V Trillet-Lenoir Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Antonio Antón; Agustí Barnadas; Jesús Florián; Nuria Ribelles; María Lomas; Juan Lao; Ana González-Quintás; Mireia Margelí; Ana Belén Paules; Javier Gayo; Manuel Ramos Journal: Clin Transl Oncol Date: 2011-04 Impact factor: 3.405